First Immune-Evading human Islet Cell Organoids Controlled Diabetes in Mice
Salk Institute scientists harnessed stem-cell technology to create the first human pancreatic cells that produce insulin and can evade immune systems. These \”immune-shielded\” human isletlike organoids, which were generated from induced pluripotent cells (iPSCs), controlled blood sugar after being transplanted into a mouse diabetes model without using immunosuppressive medications. Researchers suggest that the researchers’ achievement represents a significant advance in the search for a safe, effective treatment for type one diabetes (T1D), affecting an estimated 1.6 millions people in the United States at a cost $14.4 billion per year.
Ronald Evans, PhD (March of Dimes Chair in molecular & developmental biology) said that most type 1 diabetics were children or teenagers. Evans is the senior author of a paper published by Nature. This is a chronic disease that has historically been difficult to treat with drugs. We hope that regenerative medicines in combination with immuno shielding can make an important difference in the field. By replacing damaged cells with lab generated human islet-like clusters of cell that produce insulin on demand.
Evans and his colleagues published a paper entitled \”Immune evasive human organoids that ameliorate diabetes.\”
Source:
Diabetes Controlled in Mice Using First Immune-Evading Human Islet Cell Organoids
